Washington, District of Columbia 2021-03-31 12:21:07 –
The head of the European Medicines Agency said Wednesday that there was “no evidence” in favor of limiting the use of AstraZeneca’s coronavirus vaccine in any population.
Berlin (AP) — The director of the European Medicines Agency said Wednesday that there was “no evidence” in favor of limiting the use of AstraZeneca’s coronavirus vaccine in any population. shot.
However, EMA Secretary-General Emer Cooke said her Amsterdam-based agency is still investigating reports of new cases and will provide further assessments next week.
On Tuesday, an independent German Vaccine Expert Committee should give regular injections of AstraZeneca to people under the age of 60 due to an increasing number of reports of abnormal blood clots in the days following vaccination. I said it wasn’t.
The German government can follow this recommendation and make exceptions in consultation with doctors, but said that vaccines from UK and Swedish companies will be prioritized for people over the age of 60.
The move spotlighted the European Medicines Agency, which approved the AstraZeneca vaccine in January, and the benefits of the vaccine risked after some European countries stopped using it earlier this month because of fear of blood clots. Said to exceed.
“According to current scientific knowledge, there is no evidence to support limiting the use of this vaccine in any population,” Cook told reporters.
She said the authorities’ assessment was based on 62 abnormal blood clots, including 14 deaths reported to the EMA worldwide by March 22. These figures include, but not all, “significant” cases reported by Germany, she said.
German regulators said 31 rare blood clots were reported in the heads of AstraZeneca vaccinated people, killing nine by March 29, and the number reported domestically by March 22. It is about twice as much as.
Cooke said the EMA would include the German case in the review, “forming some of the ongoing assessments carried out by the Commission, as well as additional cases reported by other countries and regions.” Said.
Based on the numbers reported to the authorities so far, she said, there were 4.8 cases of rare blood clots per million doses of the AstraZeneca vaccine.
“For BioNTech vaccines based on the same criteria, there were 0.2 cases per million,” Cook added, referring to a shot from a German biotechnology company co-developed with US pharmaceutical giant Pfizer. “And for a modela vaccine based on the same criteria, the number of cases per million is zero, but that probably reflects much less Moderna use in Europe today.”
She said EMA experts have so far not identified potential risk factors for blood clots and have not established a causal link to the AstraZeneca vaccine.
“Linking is possible and nothing more can be said at this time,” Cook said.
Follow the AP’s pandemic coverage at:
Copyright © 2021 AP communication. all rights reserved. This material may not be published, broadcast, written, or redistributed.
EU says ‘no evidence’ to restrict use of AstraZeneca vaccine Source link EU says ‘no evidence’ to restrict use of AstraZeneca vaccine